Trump administration ends key drug pricing proposal
The Washington Post and other outlets reported that the administration has withdrawn a proposal to end rebates between pharmacy benefit managers and drugmakers.
The Washington Post and other outlets reported that the administration has withdrawn a proposal to end rebates between pharmacy benefit managers and drugmakers.
"Earlier concerns that the market would collapse or insurer exits would lead to counties with no coverage available at all have proven unfounded," the Kaiser Family Foundation wrote in an analysis.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A order released Monday directs the Department of Health and Human Services to start the rulemaking process to require that providers divulge the prices that patients and insurers pay in a readable format.
The Affordable Care Act requires employer-sponsored group health plans to cover pre-existing conditions for all individuals regardless of prior coverage.
In his decision, U.S. District Judge John Bates called the policy an "end-run" around the patient protections and regulations established with the passage of the Affordable Care Act.
While the policy has not yet gone into effect in Kentucky, data from the Arkansas Department of Human Services found that more than 18,000 people in the state have lost coverage due to the work requirements that were first introduced last year.
This recent statement goes further in backing the complete invalidation of the ACA, which includes provisions that range from Medicaid expansion to calorie labeling to protections for pre-existing conditions.
Creating a rule requiring these organizations to publicize the results of these arrangements would put more power in patients' hand and push the healthcare industry towards being more consumer friendly, a leading priority of the Trump Administration.
Another proposal, to revoke safe-harbor protections under the Anti-Kickback Statute for biopharma-PBM rebates, drew praise from speakers in a panel at the BIO CEO & Investor Conference Tuesday.
In a post on its website by an executive, the company said it would begin including list price and out-of-pocket cost information for an anticoagulant later this quarter.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
The proposed rule, which will be officially published on Wednesday, is part of the Trump administration's blueprint for reducing out-of-pocket drug prices. However, others have said it could raise premiums and have doubted how much power the administration truly has.
Science magazine reported that the move put the brakes on a preclinical HIV study and follows the cancellation of a contract between the FDA and a California-based company that supplies fetal tissue for medical research.
Current ACA subsidy programs are required to be based on income. Under the rules laid out by CMS states would be able to base subsidies on other factors potentially leaving lower-income, older and sicker patients with less comprehensive coverage options.
The company emphasized that the increases mostly amount to 3-5 percent and affect only 10 percent of its portfolio, but declined to reveal which drugs are affected.
Accusations of "freeloading" seen as misleading, and the proposed changes - which would start in 2020 - wouldn't help patients covered under Part D or commercial plans.